The Food and Drug Administration has granted approval for the first flu vaccine that uses mRNA technology, according to Moderna. This development opens a path for a new vaccination option aimed at individuals aged 50 and above, targeting protection against influenza.
Moderna revealed that the newly approved vaccine will likely become available at select retailers in the upcoming weeks. This announcement follows discussions and controversies, including skepticism from Robert F. Kennedy Jr. regarding mRNA technology.
A photograph from 2024 shows a researcher working at Moderna’s headquarters in Cambridge, Massachusetts, illustrating the ongoing efforts in mRNA vaccine development.
New Insights into PMOS and GLP-1 Drugs 
Public Health Challenges with Proposed Vaccination Order 
Understanding Medicare Extra Help and Its Benefits 
Trump’s Remarks on Childhood Vaccines Spark Debate 
CDC Reports Drug-Resistant Fungus Candida Auris Cases Across 27 States 
Medicaid Coverage and Its Impact on Pediatric Care